{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T09:55:11Z","timestamp":1789206911552,"version":"build-2803163510"},"reference-count":88,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,8,1]],"date-time":"2024-08-01T00:00:00Z","timestamp":1722470400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,26]],"date-time":"2024-05-26T00:00:00Z","timestamp":1716681600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["IJC Heart & Vasculature"],"published-print":{"date-parts":[[2024,8]]},"DOI":"10.1016\/j.ijcha.2024.101434","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T04:54:14Z","timestamp":1718340854000},"page":"101434","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease"],"prefix":"10.1016","volume":"53","author":[{"given":"Ruida","family":"Cai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinhao","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Menghui","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengjun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quanyou","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MengYa","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen-gang","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feifeng","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcha.2024.101434_b0005","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.yjmcc.2019.09.001","article-title":"Molecular machinery and interplay of apoptosis and autophagy in coronary heart disease","volume":"136","author":"Dong","year":"2019","journal-title":"J Mol Cell Cardiol"},{"issue":"10","key":"10.1016\/j.ijcha.2024.101434_b0010","doi-asserted-by":"crossref","first-page":"e1332","DOI":"10.1016\/S2214-109X(19)30318-3","article-title":"revised models to estimate risk in 21 global regions","volume":"7","author":"World Health Organization cardiovascular disease risk charts","year":"2019","journal-title":"The Lancet. Global Health"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101434_b0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.cpcardiol.2020.100655","article-title":"Obesity and Coronary Heart Disease: Epidemiology, Pathology, and Coronary Artery Imaging","volume":"46","author":"Katta","year":"2021","journal-title":"Curr Probl Cardiol"},{"issue":"10","key":"10.1016\/j.ijcha.2024.101434_b0020","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11886-021-01568-2","volume":"23","author":"McEvoy","year":"2021","journal-title":"Curr Cardiol Rep"},{"key":"10.1016\/j.ijcha.2024.101434_b0025","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejim.2020.07.006","article-title":"Hyperuricaemia and gout in cardiovascular, metabolic and kidney disease","volume":"80","author":"Borghi","year":"2020","journal-title":"Eur J Intern Med"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101434_b0030","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s40265-019-01081-5","article-title":"Cardiovascular Disease in Gout and the Protective Effect of Treatments Including Urate-Lowering Therapy","volume":"79","author":"Gupta","year":"2019","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101434_b0035","doi-asserted-by":"crossref","first-page":"413","DOI":"10.3390\/genes1030413","article-title":"Programming pluripotent precursor cells derived from Xenopus embryos to generate specific tissues and organs","volume":"1","author":"Borchers","year":"2010","journal-title":"Genes (basel)"},{"key":"10.1016\/j.ijcha.2024.101434_b0040","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.582680","article-title":"Uric Acid and Cardiovascular Disease: An Update From Molecular Mechanism to Clinical Perspective","volume":"11","author":"Yu","year":"2020","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.ijcha.2024.101434_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2022.911968","article-title":"Excess Uric Acid Induces Gouty Nephropathy Through Crystal Formation: A Review of Recent Insights","volume":"13","author":"Mei","year":"2022","journal-title":"Front Endocrinol (lausanne)"},{"issue":"7","key":"10.1016\/j.ijcha.2024.101434_b0050","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.mayocp.2022.02.027","article-title":"Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications","volume":"97","author":"Leung","year":"2022","journal-title":"Mayo Clin Proc"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0055","doi-asserted-by":"crossref","first-page":"58","DOI":"10.3390\/medicina57010058","article-title":"Therapeutic Strategies for the Treatment of Chronic Hyperuricemia: An Evidence-Based Update","volume":"57","author":"Cicero","year":"2021","journal-title":"Medicina"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101434_b0060","doi-asserted-by":"crossref","DOI":"10.1016\/j.berh.2020.101501","article-title":"Allopurinol hypersensitivity: Pathogenesis and prevention","volume":"34","author":"Stamp","year":"2020","journal-title":"Best Practice & Research Clinical Rheumatology"},{"key":"10.1016\/j.ijcha.2024.101434_b0065","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.925219","article-title":"Review of Urate-Lowering Therapeutics: From the Past to the Future","volume":"13","author":"Jenkins","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.ijcha.2024.101434_b0070","doi-asserted-by":"crossref","DOI":"10.7573\/dic.212581","article-title":"Efficacy and safety of lesinurad for the treatment of hyperuricemia in gout","volume":"8","author":"P\u00e9rez-Ruiz","year":"2019","journal-title":"Drugs in Context"},{"key":"10.1016\/j.ijcha.2024.101434_b0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2021.101882","article-title":"Xanthine oxidoreductase: One enzyme for multiple physiological tasks","volume":"41","author":"Bortolotti","year":"2021","journal-title":"Redox Biology"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0080","doi-asserted-by":"crossref","first-page":"265","DOI":"10.2147\/VHRM.S4265","article-title":"Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress","volume":"5","author":"George","year":"2009","journal-title":"Vascular Health and Risk Management"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101434_b0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000512178","article-title":"Clinical Effects of Xanthine Oxidase Inhibitors in Hyperuricemic Patients","volume":"30","author":"Cicero","year":"2021","journal-title":"Medical Principles and Practice"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101434_b0090","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1093\/ndt\/gft378","article-title":"Effects of uric acid-lowering therapy on renal outcomes: a systematic review and meta-analysis","volume":"29","author":"Bose","year":"2014","journal-title":"Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101434_b0095","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s40265-015-0360-7","article-title":"Febuxostat: a review of its use in the treatment of hyperuricaemia in patients with gout","volume":"75","author":"Frampton","year":"2015","journal-title":"Drugs"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101434_b0100","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1517\/14656566.2015.985588","article-title":"Febuxostat for the treatment of gout","volume":"16","author":"Bridgeman","year":"2015","journal-title":"Expert Opinion on Pharmacotherapy"},{"key":"10.1016\/j.ijcha.2024.101434_b0105","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.998441","article-title":"Cardiovascular safety of febuxostat and allopurinol in patients with gout: A meta-analysis","volume":"13","author":"Guan","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.ijcha.2024.101434_b0110","doi-asserted-by":"crossref","first-page":"bap024","DOI":"10.1093\/database\/bap024","article-title":"Phenol-Explorer: an online comprehensive database on polyphenol contents in foods","volume":"2010","author":"Neveu","year":"2010","journal-title":"Database"},{"issue":"9","key":"10.1016\/j.ijcha.2024.101434_b0115","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1016\/0031-6989(85)90041-4","article-title":"Inhibitory action of quercetin on xanthine oxidase and xanthine dehydrogenase activity","volume":"17","author":"Bindoli","year":"1985","journal-title":"Pharmacological Research Communications"},{"key":"10.1016\/j.ijcha.2024.101434_b0120","unstructured":"D. Sacks, B. Baxter, B.C.V. Campbell, J.S. Carpenter, C. Cognard, D. Dippel, M. Eesa, U. Fischer, K. Hausegger, J.A. Hirsch, M. Shazam Hussain, O. Jansen, M.V. Jayaraman, A.A. Khalessi, B.W. Kluck, S. Lavine, P.M. Meyers, S. Ramee, D.A. R\u00fcfenacht, C.M. Schirmer, D. Vorwerk, Multisociety Consensus Quality Improvement Revised Consensus Statement for Endovascular Therapy of Acute Ischemic Stroke, International journal of stroke : official journal of the International Stroke Society 13(6) (2018) 612-632."},{"issue":"7","key":"10.1016\/j.ijcha.2024.101434_b0125","first-page":"918","article-title":"A review on benefits of quercetin in hyperuricemia and gouty arthritis","volume":"30","author":"Nutmakul","year":"2022","journal-title":"Saudi Pharmaceutical Journal : SPJ : the Official Publication of the Saudi Pharmaceutical Society"},{"key":"10.1016\/j.ijcha.2024.101434_b0130","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ijcard.2015.08.109","article-title":"Regulation of uric acid metabolism and excretion","volume":"213","author":"Maiuolo","year":"2016","journal-title":"International Journal of Cardiology"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101434_b0135","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1007\/s00467-013-2549-x","article-title":"Uric acid and the kidney","volume":"29","author":"Fathallah-Shaykh","year":"2013","journal-title":"Pediatric Nephrology"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101434_b0140","doi-asserted-by":"crossref","first-page":"89","DOI":"10.2169\/internalmedicine.49.2597","article-title":"Effect of Fenofibrate on Uric Acid Metabolism and Urate Transporter 1","volume":"49","author":"Uetake","year":"2010","journal-title":"Internal Medicine"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101434_b0145","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/S0272-6386(99)70093-4","article-title":"Effect of fenofibrate on serum uric acid levels","volume":"34","author":"Liamis","year":"1999","journal-title":"American Journal of Kidney Diseases"},{"key":"10.1016\/j.ijcha.2024.101434_b0150","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.phrs.2015.09.012","article-title":"Plasma uric acid concentrations are reduced by fenofibrate: A systematic review and meta-analysis of randomized placebo-controlled trials","volume":"102","author":"Derosa","year":"2015","journal-title":"Pharmacological Research"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101434_b0155","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.ahj.2004.04.005","article-title":"Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia","volume":"148","author":"Milionis","year":"2004","journal-title":"American Heart Journal"},{"issue":"9","key":"10.1016\/j.ijcha.2024.101434_b0160","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40265-016-0591-2","article-title":"Impact of Statin Therapy on Plasma Uric Acid Concentrations: A Systematic Review and Meta-Analysis","volume":"76","author":"Derosa","year":"2016","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101434_b0165","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1177\/1074248419838517","article-title":"Atorvastatin and Fenofibrate Exert Opposite Effects on the Vascularization and Characteristics of Visceral Adipose Tissue in New Zealand White Rabbits","volume":"24","author":"Mondrag\u00f3n-Garc\u00eda","year":"2019","journal-title":"Journal of Cardiovascular Pharmacology and Therapeutics"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101434_b0170","doi-asserted-by":"crossref","first-page":"96","DOI":"10.17925\/EE.2022.18.2.96","article-title":"Assessing the Incidence of New-onset Diabetes Mellitus with Statin Use: A Systematic Review of the Systematic Reviews and Meta-analyses","volume":"18","author":"Singh","year":"2022","journal-title":"TouchREVIEWS in Endocrinology"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101434_b0175","doi-asserted-by":"crossref","first-page":"663","DOI":"10.2215\/CJN.11480821","article-title":"SGLT2 Inhibition and Uric Acid Excretion in Patients with Type 2 Diabetes and Normal Kidney Function","volume":"17","author":"Suijk","year":"2022","journal-title":"Clinical Journal of the American Society of Nephrology"},{"key":"10.1016\/j.ijcha.2024.101434_b0180","doi-asserted-by":"crossref","unstructured":"V. Bassi, O. Fattoruso, The Role of Fractional Excretion of Uric Acid in the Differential Diagnosis of Hypotonic Hyponatraemia in Patients with Diuretic Therapy, Cureus (2020).","DOI":"10.7759\/cureus.7762"},{"issue":"11","key":"10.1016\/j.ijcha.2024.101434_b0185","first-page":"2836","article-title":"Antidiuretic Effect of Hydrochlorothiazide in Lithium-Induced Nephrogenic Diabetes Insipidus Is Associated with Upregulation of Aquaporin-2","volume":"15","author":"Kim","year":"2004","journal-title":"Na-Cl Co-Transporter, and Epithelial Sodium Channel, Journal of the American Society of Nephrology"},{"issue":"12","key":"10.1016\/j.ijcha.2024.101434_b0190","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1080\/14740338.2020.1836151","article-title":"Safety implications of combining ACE inhibitors with thiazides for the treatment of hypertensive patients","volume":"19","author":"Borghi","year":"2020","journal-title":"Expert Opinion on Drug Safety"},{"issue":"10","key":"10.1016\/j.ijcha.2024.101434_b0195","first-page":"F958","article-title":"Everything we always wanted to know about furosemide but were afraid to ask, American Journal of Physiology-Renal","volume":"310","author":"Huang","year":"2016","journal-title":"Physiology"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0200","doi-asserted-by":"crossref","first-page":"7378","DOI":"10.1038\/s41598-021-86962-0","article-title":"Uric acid shown to contribute to increased oxidative stress level independent of xanthine oxidoreductase activity in MedCity21 health examination registry","volume":"11","author":"Kurajoh","year":"2021","journal-title":"Scientific Reports"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101434_b0205","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.3904\/kjim.2020.410","article-title":"Renal effects of uric acid: hyperuricemia and hypouricemia","volume":"35","author":"Park","year":"2020","journal-title":"The Korean Journal of Internal Medicine"},{"key":"10.1016\/j.ijcha.2024.101434_b0210","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cca.2018.05.046","article-title":"Uric acid and cardiovascular disease","volume":"484","author":"Ndrepepa","year":"2018","journal-title":"Clinica Chimica Acta"},{"issue":"15","key":"10.1016\/j.ijcha.2024.101434_b0215","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in Patients with Chronic Kidney Disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"The New England Journal of Medicine"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0220","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1111\/dom.15295","article-title":"The effect of empagliflozin and fenofibrate therapies, alone and in combination, on the serum urate concentration in hyperuricaemic type 2 diabetes","volume":"26","author":"Davis","year":"2024","journal-title":"Diabetes, Obesity & Metabolism"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101434_b0225","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1001\/jamacardio.2022.5608","article-title":"Association of Dapagliflozin Use With Clinical Outcomes and the Introduction of Uric Acid-Lowering Therapy and Colchicine in Patients With Heart Failure With and Without Gout: A Patient-Level Pooled Meta-analysis of DAPA-HF and DELIVER","volume":"8","author":"Butt","year":"2023","journal-title":"JAMA Cardiology"},{"issue":"36","key":"10.1016\/j.ijcha.2024.101434_b0230","doi-asserted-by":"crossref","first-page":"3435","DOI":"10.1093\/eurheartj\/ehac320","article-title":"Uric acid and sodium-glucose cotransporter-2 inhibition with empagliflozin in heart failure with reduced ejection fraction: the EMPEROR-reduced trial","volume":"43","author":"Doehner","year":"2022","journal-title":"European Heart Journal"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0235","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1111\/dom.14559","article-title":"Empagliflozin and uric acid metabolism in diabetes: A post hoc analysis of the EMPA-REG OUTCOME trial","volume":"24","author":"Ferreira","year":"2021","journal-title":"Diabetes, Obesity and Metabolism"},{"key":"10.1016\/j.ijcha.2024.101434_b0240","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.diabres.2019.04.008","article-title":"Empagliflozin versus dapagliflozin in patients with type 2 diabetes inadequately controlled with metformin, glimepiride and dipeptidyl peptide 4 inhibitors: A 52-week prospective observational study","volume":"151","author":"Ku","year":"2019","journal-title":"Diabetes Research and Clinical Practice"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101434_b0245","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.bbrc.2019.02.141","article-title":"TXNIP-mediated nuclear factor-\u03baB signaling pathway and intracellular shifting of TXNIP in uric acid-induced NLRP3 inflammasome","volume":"511","author":"Kim","year":"2019","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101434_b0250","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1007\/s10753-017-0542-4","article-title":"Quercetin and Ascorbic Acid Suppress Fructose-Induced NLRP3 Inflammasome Activation by Blocking Intracellular Shuttling of TXNIP in Human Macrophage Cell Lines","volume":"40","author":"Choe","year":"2017","journal-title":"Inflammation"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101434_b0255","doi-asserted-by":"crossref","first-page":"701","DOI":"10.3390\/nu13020701","article-title":"Role of Vitamin C in Prophylaxis and Treatment of Gout\u2014A Literature Review","volume":"13","author":"Brzezi\u0144ska","year":"2021","journal-title":"Nutrients"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0260","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.jjcc.2020.12.013","article-title":"Uric acid and cardiovascular disease: A clinical review","volume":"78","author":"Saito","year":"2021","journal-title":"Journal of Cardiology"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101434_b0265","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1006\/abbi.1999.1491","article-title":"Uric acid oxidation by peroxynitrite: multiple reactions, free radical formation, and amplification of lipid oxidation","volume":"372","author":"Santos","year":"1999","journal-title":"Archives of Biochemistry and Biophysics"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0270","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/imr.12218","article-title":"Macrophage phenotypes in atherosclerosis","volume":"262","author":"Colin","year":"2014","journal-title":"Immunological Reviews"},{"key":"10.1016\/j.ijcha.2024.101434_b0275","first-page":"7919165","article-title":"Correlation of Serum Uric Acid Levels with Nonculprit Plaque Instability in Patients with Acute Coronary Syndromes: A 3-Vessel Optical Coherence Tomography Study","volume":"2018","author":"Zhang","year":"2018","journal-title":"Biomed Res Int"},{"issue":"12","key":"10.1016\/j.ijcha.2024.101434_b0280","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.10.012","article-title":"Role of Hyperhomocysteinemia and Hyperuricemia in Pathogenesis of Atherosclerosis","volume":"26","author":"Zhao","year":"2017","journal-title":"J Stroke Cerebrovasc Dis"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101434_b0285","doi-asserted-by":"crossref","first-page":"C1183","DOI":"10.1152\/ajpcell.00075.2008","article-title":"Uric acid decreases NO production and increases arginase activity in cultured pulmonary artery endothelial cells","volume":"295","author":"Zharikov","year":"2008","journal-title":"American Journal of Physiology-Cell Physiology"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101434_b0290","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ceca.2012.01.003","article-title":"Hyperuricemia induces endothelial dysfunction via mitochondrial Na+\/Ca2+ exchanger-mediated mitochondrial calcium overload","volume":"51","author":"Hong","year":"2012","journal-title":"Cell Calcium"},{"key":"10.1016\/j.ijcha.2024.101434_b0295","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.niox.2013.04.003","article-title":"Uric acid attenuates nitric oxide production by decreasing the interaction between endothelial nitric oxide synthase and calmodulin in human umbilical vein endothelial cells: A mechanism for uric acid-induced cardiovascular disease development","volume":"32","author":"Park","year":"2013","journal-title":"Nitric Oxide"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101434_b0300","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1053\/pcad.2003.YPCAD13","article-title":"Smoking and endothelial function","volume":"45","author":"Puranik","year":"2003","journal-title":"Progress in Cardiovascular Diseases"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101434_b0305","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/j.1365-2796.2009.02133.x","article-title":"Uric acid and risk of myocardial infarction, stroke and congestive heart failure in 417,734 men and women in the Apolipoprotein MOrtality RISk study (AMORIS)","volume":"266","author":"Holme","year":"2009","journal-title":"Journal of Internal Medicine"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101434_b0310","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1161\/CIRCHEARTFAILURE.108.797662","article-title":"Hyperuricemia and incident heart failure","volume":"2","author":"Krishnan","year":"2009","journal-title":"Circulation. Heart Failure"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101434_b0315","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.ijcard.2009.01.010","article-title":"Association between hyperuricemia and incident heart failure among older adults: a propensity-matched study","volume":"142","author":"Ekundayo","year":"2010","journal-title":"Int J Cardiol"},{"issue":"8","key":"10.1016\/j.ijcha.2024.101434_b0320","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.amjcard.2010.06.023","article-title":"Effect of serum insulin on the association between hyperuricemia and incident heart failure","volume":"106","author":"Desai","year":"2010","journal-title":"The American Journal of Cardiology"},{"key":"10.1016\/j.ijcha.2024.101434_b0325","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijcard.2017.11.083","article-title":"Serum uric acid as a potential marker for heart failure risk in men on antihypertensive treatment: The British Regional Heart Study","volume":"252","author":"Wannamethee","year":"2018","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0330","first-page":"25","article-title":"Uric acid as a predictor of all-cause mortality in heart failure: a meta-analysis, Congestive heart failure (Greenwich","volume":"17","author":"Tamariz","year":"2011","journal-title":"Conn.)"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0335","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/eurjhf\/hft132","article-title":"Uric acid and risk of heart failure: a systematic review and meta-analysis","volume":"16","author":"Huang","year":"2014","journal-title":"European Journal of Heart Failure"},{"key":"10.1016\/j.ijcha.2024.101434_b0340","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.ijcard.2015.08.089","article-title":"Uric acid and xanthine oxidase in heart failure - Emerging data and therapeutic implications","volume":"213","author":"Doehner","year":"2016","journal-title":"Int J Cardiol"},{"issue":"11","key":"10.1016\/j.ijcha.2024.101434_b0345","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1136\/heartjnl-2012-302535","article-title":"The role of uric acid in the pathogenesis of human cardiovascular disease","volume":"99","author":"Kanbay","year":"2013","journal-title":"Heart"},{"issue":"5","key":"10.1016\/j.ijcha.2024.101434_b0350","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1161\/01.CIR.103.5.750","article-title":"Allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure","volume":"103","author":"Ukai","year":"2001","journal-title":"Circulation"},{"issue":"9","key":"10.1016\/j.ijcha.2024.101434_b0355","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jacc.2011.10.895","article-title":"Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts","volume":"59","author":"Hirsch","year":"2012","journal-title":"Journal of the American College of Cardiology"},{"issue":"7","key":"10.1016\/j.ijcha.2024.101434_b0360","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.cardfail.2006.05.005","article-title":"The effect of xanthine oxidase inhibition upon ejection fraction in heart failure patients: La Plata Study","volume":"12","author":"Cingolani","year":"2006","journal-title":"Journal of Cardiac Failure"},{"issue":"22","key":"10.1016\/j.ijcha.2024.101434_b0365","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1161\/01.CIR.0000017502.58595.ED","article-title":"Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies","volume":"105","author":"Doehner","year":"2002","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101434_b0370","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1161\/01.CIR.0000022140.61460.1D","article-title":"Allopurinol improves endothelial dysfunction in chronic heart failure","volume":"106","author":"Farquharson","year":"2002","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcha.2024.101434_b0375","first-page":"179","article-title":"Uric acid, heart failure survival, and the impact of xanthine oxidase inhibition, Congestive heart failure (Greenwich","volume":"18","author":"Harzand","year":"2012","journal-title":"Conn.)"},{"issue":"11","key":"10.1016\/j.ijcha.2024.101434_b0380","first-page":"1702","volume":"70","author":"Choi","year":"2018","journal-title":"N.J.)"},{"issue":"21","key":"10.1016\/j.ijcha.2024.101434_b0385","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1056\/NEJMoa1911303","article-title":"Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction","volume":"381","author":"McMurray","year":"2019","journal-title":"The New England Journal of Medicine"},{"issue":"12","key":"10.1016\/j.ijcha.2024.101434_b0390","doi-asserted-by":"crossref","first-page":"2157","DOI":"10.1136\/annrheumdis-2014-205577","article-title":"Insights into the poor prognosis of allopurinol-induced severe cutaneous adverse reactions: the impact of renal insufficiency, high plasma levels of oxypurinol and granulysin","volume":"74","author":"Chung","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.ijcha.2024.101434_b0395","series-title":"The development and evaluation of dose-prediction tools for allopurinol therapy","author":"Wright","year":"2024"},{"issue":"6","key":"10.1016\/j.ijcha.2024.101434_b0400","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.semarthrit.2008.08.006","article-title":"Colchicine update: 2008","volume":"38","author":"Terkeltaub","year":"2009","journal-title":"Seminars in Arthritis and Rheumatism"},{"key":"10.1016\/j.ijcha.2024.101434_b0405","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ (clinical Research Ed.)"},{"issue":"4\u20136","key":"10.1016\/j.ijcha.2024.101434_b0410","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/15257771003741323","article-title":"Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients","volume":"29","author":"Ogata","year":"2010","journal-title":"Nucleosides, Nucleotides & Nucleic Acids"},{"issue":"2","key":"10.1016\/j.ijcha.2024.101434_b0415","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2012.01.092","article-title":"Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials","volume":"157","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"issue":"4","key":"10.1016\/j.ijcha.2024.101434_b0420","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.jacc.2012.10.027","article-title":"Low-dose colchicine for secondary prevention of cardiovascular disease","volume":"61","author":"Nidorf","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"16","key":"10.1016\/j.ijcha.2024.101434_b0425","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1016\/j.jacc.2013.01.055","article-title":"Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients","volume":"61","author":"Deftereos","year":"2013","journal-title":"Journal of the American College of Cardiology"},{"issue":"1","key":"10.1016\/j.ijcha.2024.101434_b0430","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"10359","key":"10.1016\/j.ijcha.2024.101434_b0435","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S0140-6736(22)01657-9","article-title":"Allopurinol versus usual care in UK patients with ischaemic heart disease (ALL-HEART): a multicentre, prospective, randomised, open-label, blinded-endpoint trial","volume":"400","author":"Mackenzie","year":"2022","journal-title":"Lancet (london, England)"},{"issue":"18","key":"10.1016\/j.ijcha.2024.101434_b0440","first-page":"1","article-title":"Allopurinol and cardiovascular outcomes in patients with ischaemic heart disease: the ALL-HEART RCT and economic evaluation","volume":"28","author":"Mackenzie","year":"2024","journal-title":"Health Technology Assessment (winchester, England)"}],"container-title":["IJC Heart & Vasculature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724001003?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352906724001003?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T21:49:28Z","timestamp":1733608168000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352906724001003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8]]},"references-count":88,"alternative-id":["S2352906724001003"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101434","relation":{},"ISSN":["2352-9067"],"issn-type":[{"value":"2352-9067","type":"print"}],"subject":[],"published":{"date-parts":[[2024,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mechanism and use strategy of uric acid-lowering drugs on coronary heart disease","name":"articletitle","label":"Article Title"},{"value":"IJC Heart & Vasculature","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcha.2024.101434","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101434"}}